GSKD Stock Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£10.20 |
| 52 Week High | UK£11.15 |
| 52 Week Low | UK£8.20 |
| Beta | 0.27 |
| 1 Month Change | -8.52% |
| 3 Month Change | 7.37% |
| 1 Year Change | n/a |
| 3 Year Change | 4.08% |
| 5 Year Change | n/a |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSKD | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | -8.5% | -6.5% | -6.9% |
| 1Y | n/a | -18.6% | 303.2% |
Return vs Industry: Insufficient data to determine how GSKD performed against the AR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how GSKD performed against the AR Market.
Price Volatility
| GSKD volatility | |
|---|---|
| GSKD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AR Market | 14.5% |
| 10% least volatile stocks in AR Market | 7.3% |
Stable Share Price: GSKD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GSKD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GSKD fundamental statistics | |
|---|---|
| Market cap | US$80.64b |
| Earnings (TTM) | US$6.14b |
| Revenue (TTM) | US$37.80b |
13.2x
P/E Ratio2.1x
P/S RatioIs GSKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSKD income statement (TTM) | |
|---|---|
| Revenue | UK£30.33b |
| Cost of Revenue | UK£8.39b |
| Gross Profit | UK£21.94b |
| Other Expenses | UK£17.01b |
| Earnings | UK£4.93b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 72.34% |
| Net Profit Margin | 16.25% |
| Debt/Equity Ratio | 131.4% |
How did GSKD perform over the long term?
See historical performance and comparison